Canada: Canada Proposes Patent Act Amendments to Allow Export of Patented Drugs to Developing Countries

This article was originally published in Blakes Bulletin on Intellectual Property - December 2003


As of World AIDS Day on December 1st, 2003, HIV/AIDS remains a world health emergency. Despite the existence of treatment, the vast majority of those infected with HIV do not have access to the pharmaceutical compounds or drugs available in many developed countries such as Canada and the United States. One reason for this, according to The Joint United Nations Programme on HIV/AIDS, is that 95% of those infected with HIV live in developing countries. Similarly, many other infectious diseases, such as malaria and tuberculosis, continue to present significant public health problems in developing countries, despite the availability of treatment in the developed world.

In view of this, and prompted by a recent decision of the World Trade Organization ("WTO"), the Canadian government, in an apparent first among developed countries, recently introduced Bill C-56 which contains amendments to the Patent Act and Food & Drug Act that could allow Canadian manufacturers to export patented drugs to developing countries.

In 2001, the WTO declared that the Agreement on Trade-Related Aspects of Intellectual Property Rights ("TRIPS") should not prevent countries from taking measures to protect public health. According to the WTO, TRIPS "can and should be interpreted and implemented in a manner supportive of WTO Members’ right to protect public health and, in particular, to promote access to medicines for all." While TRIPS provides for compulsory licensing of patented drugs, any such compulsory license "… shall be authorized predominantly for the supply of the domestic market of the Member…". This presents difficulties for those developing countries that have no or insufficient manufacturing capacities in the pharmaceutical sector. In an attempt to address this, the General Council of the WTO issued a decision on August 30th, 2003, allowing drug manufacturers in developed countries, despite other persons having patent protection surrounding such pharmaceutical compounds in those countries, to manufacture such compounds and export them to the developing world.

Proposed Amendments

The recently proposed amendments in Bill C-56 would provide a mechanism whereby a Canadian pharmaceutical manufacturer could apply for and be granted a non-exclusive, non-transferable "authorization" for two years, subject to renewal, to use the subject matter of a Canadian patent solely for the purposes of manufacturing a drug and exporting that drug to an identified country. More specifically, the amendments propose that should a Canadian manufacturer ("Applicant") wish to obtain such authorization, it first must apply for and notify the Commissioner of Patents ("Commissioner") of the drug to be exported, the quantity of the drug intended to be manufactured, the patent owner ("patentee") and the patent number for each patented invention to which the drug named in the application for authorization relates, the name of the country to which the drug is intended to be exported ("Import Country") and the terms and conditions under which the drug is to be manufactured and sold for export.

In addition to the information provided above, the Applicant must produce a certified copy of the Import Country’s written notice provided to the government of Canada or pursuant to TRIPS of its need for the drug. The Applicant must also either declare that the drug to which the application relates is not patented in the Import Country, or submit evidence that the Import Country has granted or intends to grant a compulsory licence for the drug. Depending on which Import Country is to be involved, the application may also need to state that the Import Country has no or insufficient pharmaceutical manufacturing capacity for the production of the drug and/or that the Import Country is faced with a national emergency or other circumstances of extreme urgency.

Upon receipt of the application, the Commissioner must send a copy of the application to any patentees listed therein, whereby each patentee is given a "right of first refusal". Each patentee then has 30 days to provide the Commissioner with a declaration stating that the patentee, or its agent, will either supply the drug to the Import Country on terms and conditions that are no less favourable than those referred to in the application or, subject to the payment of a royalty, grant the Applicant a right to use the subject matter of the relevant patent so that the drug can be manufactured and sold for export as set out in the application.

If the patentee does not provide a declaration as noted above, the Commissioner shall authorize the use of the patented invention solely for the manufacture and export of the drug, provided that the Canadian Minister of Health (the "Minister") has notified the Commissioner that the version of the drug named in the application meets the requirements of the Food & Drug Act and its regulations. More importantly, the Minister must also notify the Commissioner that the marking, embossing, labelling and packaging of the drug to be exported pursuant to the authorization distinguishes that exported version from the version of the pharmaceutical product marketed in Canada.

Upon receipt of the authorization, the Applicant must pay the patentee a royalty in an amount equal to two per cent of the value of the pharmaceutical products exported under the authorization or, if there is more than one patentee, to each patentee within the prescribed time, a royalty in an amount equal to two per cent of the value of the pharmaceutical products exported under the authorization divided by the number of patentees.

Before exporting a drug manufactured pursuant to the above noted authorization, the Applicant must establish a website that discloses the drug to be exported, the name of the Import Country to which the drug is to be exported, the quantity of the drug that is authorized to be manufactured and sold for export and the exported version’s "distinguishing features". The effect of this novel provision remains to be seen.

Following the Commissioner granting such an authorization, the patentee may apply to the Federal Court for an order terminating the authorization if the patentee establishes any of the following: One. The application for the authorization contained any material information that is inaccurate. Two. The Applicant failed to establish the website noted above or to disclose the required information. Three. The Applicant has failed to pay, within the required time, any royalty required to be paid as a result of the authorization. Four. The drug exported to the Import Country pursuant to the authorization has been, with the knowledge of the Applicant, re-exported in a manner that is contrary to the General Council Decision and in quantities that are significant, considering the quantities originally exported.


Industry groups that represent both Canada’s research-based and generic pharmaceutical industry have commented that the proposed amendments are a first step in addressing the drug supply of developing countries. Bill C-56 appears to have support from all of the Canadian political parties represented in the House of Commons. However, the prorogation of the House of Commons on November 12, 2003, shortly after Bill C-56 was presented, makes the future of these proposed amendments uncertain. For the amendments to be passed into law, they must be submitted in the form of a new Bill, upon the resumption of Parliament. It is therefore not clear whether the proposed amendments will become law.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
27 Oct 2016, Seminar, Toronto, Canada

Please join members of the Blakes Commercial Real Estate group as they discuss five key provisions of a commercial real estate purchase agreement that are often the subject of much negotiation but are sometimes misunderstood.

1 Nov 2016, Seminar, Toronto, Canada

What is the emotional culture of your organization?

Every organization and workplace has an emotional culture that can have an impact on everything from employee performance to customer or client satisfaction.

3 Nov 2016, Seminar, Toronto, Canada

Join leading lawyers from the Blakes Pensions, Benefits & Executive Compensation group as they discuss recent updates and legal developments in pension and employee benefits law as well as strategies to identify and minimize common risks.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.